R – G L P – 3

R – G L P – 3 is a novel investigational peptide developed for the treatment of obesity, type 2 diabetes, and other metabolic disorders. This drug is a triple-hormone-receptor agonist which play crucial roles in metabolic regulation and appetite control​​.

Clinical trials have shown that R – G L P – 3 can achieve up to a 17.5% mean weight reduction at 24 weeks and 24.2% at 48 weeks​​. The phase 2 dosing titration schedule for R – G L P – 3, as part of its clinical development for weight loss and other conditions, typically involves a gradual increase in dosage over a period to minimize side effects and allow the body to adjust to the medication.

• Potential Weight Loss with Minimal Muscle Loss
• Reduce Fat Mass
• Decrease Blood Glucose and Insulin Levels
• Increase Energy Expenditure
• Lipid Oxidation

Researchers have often combined this with Ipamorelin, BPC-157, AOD-9604 or Cagrilintide.

Vial contains lyophilized product. Reconstitution solution of choice must be added before use.